SillaJen Inc (215600) - Total Liabilities
Based on the latest financial reports, SillaJen Inc (215600) has total liabilities worth ₩6.58 Billion KRW (≈ $4.46 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SillaJen Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how SillaJen Inc's total liabilities have evolved over time, based on quarterly financial data. See SillaJen Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
SillaJen Inc Competitors by Total Liabilities
The table below lists competitors of SillaJen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
China | CN¥4.23 Billion |
|
Arkade Developers Ltd
NSE:ARKADE
|
India | Rs3.09 Billion |
|
Rane (Madras) Limited
NSE:RML
|
India | Rs17.70 Billion |
|
Tiansheng Pharmaceutical Group Co Ltd
SHE:002872
|
China | CN¥679.17 Million |
|
Shandong Kehui Power Automation Co Ltd
SHG:688681
|
China | CN¥230.89 Million |
|
Squirrel Media SA
MC:SQRL
|
Spain | €163.52 Million |
|
Samsung Sdi Co Pref
KO:006405
|
Korea | ₩18.70 Trillion |
|
ACELYRIN, INC. Common Stock
NASDAQ:SLRN
|
USA | $29.27 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down SillaJen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SillaJen Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SillaJen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SillaJen Inc (2015–2024)
The table below shows the annual total liabilities of SillaJen Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.20 Billion ≈ $11.66 Million |
-11.35% |
| 2023-12-31 | ₩19.40 Billion ≈ $13.15 Million |
-20.83% |
| 2022-12-31 | ₩24.51 Billion ≈ $16.61 Million |
-8.49% |
| 2021-12-31 | ₩26.78 Billion ≈ $18.15 Million |
+9.11% |
| 2020-12-31 | ₩24.54 Billion ≈ $16.63 Million |
-12.67% |
| 2018-12-31 | ₩28.11 Billion ≈ $19.05 Million |
-14.85% |
| 2017-12-31 | ₩33.01 Billion ≈ $22.37 Million |
-56.66% |
| 2016-12-31 | ₩76.16 Billion ≈ $51.61 Million |
+15.23% |
| 2015-12-31 | ₩66.09 Billion ≈ $44.79 Million |
-- |
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more